Focus:
News
-
3 April 2020
Novartis and Incyte to trial Jakavi for Covid-19
Novartis, in alliance with Incyte, has announced plans to assess Jakavi (ruxolitinib) in a Phase III clinical trial to treat cytokine storm in patients with severe Covid-19 pneumonia.
-
3 April 2020
Apeiron Biologics gets regulatory approval for Phase II Covid-19 trial
Apeiron Biologics has secured approvals from regulatory agencies in Austria, Germany and Denmark to conduct a Phase II clinical trial of APN01 for the treatment of Covid-19.
-
2 April 2020
DCRI to trial hydroxychloroquine to prevent Covid-19
Duke Clinical Research Institute (DCRI) is set to conduct a randomised clinical trial of hydroxychloroquine to prevent Covid-19 in healthcare workers at risk of infection.
-
2 April 2020
Gilead initiates two studies of remdesivir for Covid-19 in UK
Gilead Sciences has launched two Phase III clinical trials of its investigational antiviral drug remdesivir in the UK to treat Covid-19 patients.
-
2 April 2020
EUSA Pharma reports data of siltuximab in coronavirus trial
EUSA Pharma has reported preliminary results from the SISCO study of siltuximab for the treatment of patients with Covid-19.
-
2 April 2020
CytoDyn seeks approval to trial leronlimab for severe Covid-19
Biotechnology firm CytoDyn has submitted a second clinical trial protocol to the US Food and Drug Administration (FDA) for the use of leronlimab to treat severe illness caused by Covid-19...
-
1 April 2020
Genfit says Covid-19 may not significantly delay NASH trial readout
Amid the ongoing Covid-19 pandemic, Genfit is monitoring the impact on regulatory and clinical activities associated with its existing programmes.
-
1 April 2020
InflaRx starts dosing Covid-19 patients in Europe
German biopharmaceutical firm InflaRx has enrolled and dosed the first patient in a clinical study of IFX-1 in Covid-19 patients with severe pneumonia in the Netherlands.
-
1 April 2020
TriNetX extends global network into Japan
Global health research network TriNetX has partnered with Medical Data Vision (MDV), a provider of a health claims and administrative data from more than 400 acute hospitals in Japan.
-
1 April 2020
Fujifilm commences Phase III trial of Avigan for Covid-19
Fujifilm Toyama Chemical has started a Phase III clinical trial of its antiviral influenza drug Avigan (favipiravir) for the treatment of Covid-19 patients in Japan.